🎥 Can editing the ‘dark genome’ make crops more heat tolerant?

[Disclosure: AgFunderNews’ parent company AgFunder is an investor in Plantik Biosciences.] Can editing the so-called “da…

Unilever posts decade-high beauty volume growth fueled by Desire at Scale strategy

Unilever has reported that its beauty, personal care, and home care divisions drove its H1 2026 results and delivered the best volume quarter the company has seen in over a decade. The financials indicate the effectiveness of the company’s Desire at Scale strategy at driving demand. 

EU backs lab-based SPF testing as ethical and reliable alternative to human trials

The European Commission (EC) has stated that when testing SPF, the in vitro laboratory standard is reliable and more ethical than trialing on human volunteers. 

Monteloeder by SuanNutra backs clinical proof and skin-gut axis in beauty nutrition

Monteloeder by SuanNutra says the beauty-from-within space is becoming more mainstream. The ingredients specialist says solutions are increasingly connected to other health areas, such as longevity, sleep, gut health, stress management, and overall wellness. It highlights market potential in holistic health products that are backed by scientific evidence. 

Argenx Expands Immunology Portfolio with $2.2B Buyout of Forte Biosciences

Argenx has agreed to acquire Forte Biosciences for $2.2 billion, the companies said, in a deal intended to expand the buyer’s immunology portfolio with an early clinical stage candidate that has shown promising data.

Cargill Ventures eyes renewed dealmaking as agrifoodtech resets

After two years focusing on managing its existing portfolio, Cargill Ventures is gearing up for renewed activity. The co…

永农生物招聘:海外市场、外贸销售、原药销售、采购及大区经理

永农成立于2005年1月,集团总部位于浙江省杭州市上城区,主要生产基地坐落于浙江省杭州湾上虞经济技术开发区和宁夏宁东煤化工园区。作为一家集研发、生产、销售为一体的作物保护公司,永农为全球70多个国家和地区的用户提供优质的农化产品和全方位的植保服务。

Pentixapharm raises €20.4M for Phase 3 diagnostic trial

Why it matters: The financing gives Pentixapharm the funds to test whether a noninvasive scan can help doctors choose between surgery and drug treatment for patients with primary hyperaldosteronism, also known as Conn’s syndrome, a condition that occurs when your adrenal glands make too much aldosterone.

Nova Biomedical Acquires NanoCellect Assets to Expand Cell Line Development Portfolio

Nova Biomedical acquired certain assets of NanoCellect, which develops microfluidic cell sorting technology, to expand its capabilities in cell line development and strengthen support for biopharmaceutical workflows from early research through commercial manufacturing.

Guest article: Every transformative agriculture technology becomes an infrastructure story

Gabe Youtsey is the chief innovation officer at the University of California Agriculture and Natural Resources. The view…